Hematology: curing CML with imatinib--a dream come true?

Affiliations

¹ Division of Hematology and Hematologic Malignancies, University of Utah, Huntsman Cancer Institute, 2000 Circle of Hope, Room 4280, Salt Lake City, UT 84112-5550, USA. michael.deininger@hci.utah.edu

Comment

Michael Deininger. Nat Rev Clin Oncol. 2011 Mar.

. 2011 Mar;8(3):127-8.

doi: 10.1038/nrclinonc.2011.17. Epub 2011 Feb 1.

¹ Division of Hematology and Hematologic Malignancies, University of Utah, Huntsman Cancer Institute, 2000 Circle of Hope, Room 4280, Salt Lake City, UT 84112-5550, USA. michael.deininger@hci.utah.edu

No abstract available

Comment on

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P; Intergroupe Français des Leucémies Myéloïdes Chroniques. Mahon FX, et al. Lancet Oncol. 2010 Nov;11(11):1029-35. doi: 10.1016/S1470-2045(10)70233-3. Epub 2010 Oct 19. Lancet Oncol. 2010. PMID: 20965785 Clinical Trial.